Identification of type II inhibitors targeting BRAF using privileged pharmacophores

Chemical Biology and Drug Design

Volumn 83, Issue 1, 2014, Pages 27-36

  Zhang, Qingwen ^a   Wang, Juan ^a   Wang, Fei ^a   Chen, Xiuhua ^a   He, Yunsong ^a   You, Qidong ^b   Zhou, Houyuan ^a  

^a SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

drug design; kinase; pharmacophore; type II inhibitor; urea

Indexed keywords

4 PHENYLAMINOPYRIMIDINE UREA; ANTINEOPLASTIC AGENT; B RAF KINASE; DORAMAPIMOD; IMATINIB; LINIFANIB; NILOTINIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; REGORAFENIB; SORAFENIB; TIVOZANIB; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SYNTHESIS; ENZYME CONFORMATION; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; ONCOGENE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR XENOGRAFT;

MURINAE;

DRUG DESIGN; KINASE; PHARMACOPHORE; TYPE II INHIBITOR; UREA;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; MUTATION; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS B-RAF; PYRIMIDINES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891488352     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12198     Document Type: Article

References (23)

1. Roberts P.J., Der C.J., (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene; 26: 3291-3310.
2. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., Kohno M., (1999) Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene; 18: 813-822.
3. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., et al,. (2007) Patterns of somatic mutation in human cancer genomes. Nature; 446: 153-158.
4. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., et al,. (2002) Mutations of the BRAF gene in human cancer. Nature; 417: 949-954.
5. Garnett M.J., Marais R., (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell; 6: 313-319.
6. Wilhelm S.M., Carter C., Tang L.Y., Wilkie D., McNabola A., Rong H., Chen C., et al,. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res; 64: 7099-7109.
7. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., et al,. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature; 467: 596-599.
8. Wilhelm S.M., Dumas J., Adnane L., Lynch M., Carter C.A., Schütz G., Thierauch K.-H., Zopf D., (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer; 129: 245-255.
9. Rheault T.R., Stellwagen J.C., Adjabeng G.M., Hornberger K.R., Petrov K.G., Waterson A.G., Dickerson S.H., et al,. (2013) Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett; 4: 358-362.
10. Zambon A., Niculescu-Duvaz I., Niculescu-Duvaz D., Marais R., Springer C.J., (2012) Small molecule inhibitors of BRAF in clinical trials. Bioorg Med Chem Lett; 22: 789-792.
11. Zhang Q., Diao Y., Wang F., Fu Y., Tang F., You Q., Zhou H., (2013) Design and discovery of 4-anilinoquinazoline ureas as multikinase inhibitors targeting BRAF, VEGFR-2 and EGFR. Med Chem Commun; 4: 979-986.
12. Dumas J., Smith R.A., Lowinger T.B., (2004) Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Devel; 7: 600-616.
13. Bridges A.J., (2001) Chemical inhibitors of protein kinases. Chem Rev; 101: 2541-2571.
14. Liu Y., Gray N.S., (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol; 2: 358-364.
15. Liao J.J.-L., (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem; 50: 409-424.
16. Niculescu-Duvaz D., Gaulon C., Dijkstra H.P., Niculescu-Duvaz I., Zambon A., Menard D., Suijkerbuijk B.M.J.M., et al,. (2009) Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). J Med Chem; 52: 2255-2264.
17. Henze H.R., Clegg W.J., Smart C.W., (1952) Researches on pyrimidines: certain derivatives of 2-methylpyrimidine. J Org Chem; 17: 1320-1327.
18. Manley P.W., Breitenstein W., Bruggen J., Cowan-Jacob S.W., Furet P., Mestan J., Meyer T., (2004) Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDCFR kinases. Bioorg Med Chem Lett; 14: 5793-5797.
19. Zhang Q., Zhou H., (2012) Urea derivatives and preparation, intermediates and uses thereof. WO 2012/139499 A1.
20. Bankston D., Dumas J., Natero R., Riedl B., Monahan M.K., Sibley R., (2002) A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer. Org Process Res Dev; 6: 777-781.
21. Zhang Q., Zhou H., You Q., (2010) One-pot synthesis of anticancer drug sorafenib tosylate. Zhongguo Yao Wu Hua Xue Za Zhi; 20: 358-361.
22. Dietrich J., Hulme C., Hurley L.H., (2010) The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796. Bioorg Med Chem; 18: 5738-5748.
23. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Cancer Genome Project, Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R., (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell; 116: 855-867.